Stocksigma LogoStocksigma Logo

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change

Tavexia Lifecare's board approved Q2 un-audited results for the period ended 30th Sep'26, reporting consolidated revenue from operations of ₹503.94 lakhs

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change

Sattva Sukun Lifecare Ltd · Financial Result · 05 Nov 2026, 3:03 am

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change Tavexia Lifecare's board approved Q2 un-audited results for the period ended 30th Sep'26, reporting consolidated revenue from operations of ₹503.94 lakhs compared to ₹1,684.33 lakhs YoY, with a net loss of ₹40.12 lakhs versus a net profit of ₹78.21 lakhs in the prior-year quarter. Standalone net loss stood at ₹51.40 lakhs. The board granted in-principle approval to raise up to ₹68 crore via securities issuance to finance its proposed 60% stake acquisition in Meyonex Pharmaceuticals. Additionally, RTA operations will transition from Niche Technologies to Skyline Financial Services.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements